Ipinzan (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride primarily decreases the amount of glucose produced by the liver and improves the sensitivity of muscle cells to insulin, allowing more efficient uptake of glucose from the bloodstream.

The dosage of Ipinzan is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Ipinzan in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipinzan combines a Biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering both insulin‑sensitising and incretin‑enhancing effects. This dual action can provide better glycaemic control than metformin alone and may have a lower risk of hypoglycaemia compared with sulfonylureas.

Ipinzan should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and potency.

Ipinzan is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycaemia, especially when used with insulin or sulfonylureas. Patients should be educated on early signs and seek immediate medical attention if they occur.

Ipinzan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.